Stock Movers Ventyx Rises on Eli Lilly Talks, Mobileye, Strategy Rises
Jan 6, 2026
Carmen Reinecke, a deputy team leader for U.S. equities at Bloomberg News, shares insights on the stock market's latest movers. Eli Lilly's talks to acquire Ventyx Biosciences for over $1 billion sent Ventyx shares soaring nearly 60%. Mobileye's $900 million acquisition of Mentee Robotics hints at a future filled with humanoid robots. Additionally, MSCI's decision to maintain Strategy in global benchmarks surprises investors, giving a boost to its shares. Tune in for a lively discussion on these significant market developments!
AI Snips
Chapters
Transcript
Episode notes
Big Pharma Eyes Inflammatory Biotech
- Eli Lilly is reportedly in advanced talks to buy Ventyx for over $1 billion, which almost doubles its prior valuation.
- The acquisition interest highlights big-pharma appetite for biotech focused on inflammatory diseases like Crohn's and rheumatoid arthritis.
M&A Rumors Trigger Volatile Moves
- Ventyx shares were halted for volatility after the acquisition report, then resumed with a large postmarket jump.
- Market reaction underscores how M&A rumors can rapidly reprice small-cap biotech companies.
Mobileye Moves Into Robotics
- Mobileye will acquire Israeli startup Mentee Robotics in a deal valued at about $900 million using cash and stock.
- The purchase signals Mobileye's push from self-driving systems toward humanoid and factory robots integration.